S&P 500   4,584.10 (+0.76%)
DOW   36,115.37 (+0.17%)
QQQ   390.43 (+1.40%)
AAPL   194.09 (+0.92%)
MSFT   371.03 (+0.60%)
META   327.00 (+3.01%)
GOOGL   136.99 (+5.36%)
AMZN   146.59 (+1.43%)
TSLA   241.40 (+0.85%)
NVDA   464.07 (+1.99%)
NIO   7.49 (-3.35%)
BABA   72.26 (+1.08%)
AMD   127.63 (+9.25%)
T   17.03 (+0.53%)
F   10.83 (+1.31%)
MU   73.67 (+0.74%)
CGC   0.72 (+3.01%)
GE   118.85 (-0.80%)
DIS   92.37 (+0.95%)
AMC   6.80 (+0.15%)
PFE   28.67 (-0.42%)
PYPL   58.47 (-1.78%)
XOM   98.34 (-0.78%)
S&P 500   4,584.10 (+0.76%)
DOW   36,115.37 (+0.17%)
QQQ   390.43 (+1.40%)
AAPL   194.09 (+0.92%)
MSFT   371.03 (+0.60%)
META   327.00 (+3.01%)
GOOGL   136.99 (+5.36%)
AMZN   146.59 (+1.43%)
TSLA   241.40 (+0.85%)
NVDA   464.07 (+1.99%)
NIO   7.49 (-3.35%)
BABA   72.26 (+1.08%)
AMD   127.63 (+9.25%)
T   17.03 (+0.53%)
F   10.83 (+1.31%)
MU   73.67 (+0.74%)
CGC   0.72 (+3.01%)
GE   118.85 (-0.80%)
DIS   92.37 (+0.95%)
AMC   6.80 (+0.15%)
PFE   28.67 (-0.42%)
PYPL   58.47 (-1.78%)
XOM   98.34 (-0.78%)
S&P 500   4,584.10 (+0.76%)
DOW   36,115.37 (+0.17%)
QQQ   390.43 (+1.40%)
AAPL   194.09 (+0.92%)
MSFT   371.03 (+0.60%)
META   327.00 (+3.01%)
GOOGL   136.99 (+5.36%)
AMZN   146.59 (+1.43%)
TSLA   241.40 (+0.85%)
NVDA   464.07 (+1.99%)
NIO   7.49 (-3.35%)
BABA   72.26 (+1.08%)
AMD   127.63 (+9.25%)
T   17.03 (+0.53%)
F   10.83 (+1.31%)
MU   73.67 (+0.74%)
CGC   0.72 (+3.01%)
GE   118.85 (-0.80%)
DIS   92.37 (+0.95%)
AMC   6.80 (+0.15%)
PFE   28.67 (-0.42%)
PYPL   58.47 (-1.78%)
XOM   98.34 (-0.78%)
S&P 500   4,584.10 (+0.76%)
DOW   36,115.37 (+0.17%)
QQQ   390.43 (+1.40%)
AAPL   194.09 (+0.92%)
MSFT   371.03 (+0.60%)
META   327.00 (+3.01%)
GOOGL   136.99 (+5.36%)
AMZN   146.59 (+1.43%)
TSLA   241.40 (+0.85%)
NVDA   464.07 (+1.99%)
NIO   7.49 (-3.35%)
BABA   72.26 (+1.08%)
AMD   127.63 (+9.25%)
T   17.03 (+0.53%)
F   10.83 (+1.31%)
MU   73.67 (+0.74%)
CGC   0.72 (+3.01%)
GE   118.85 (-0.80%)
DIS   92.37 (+0.95%)
AMC   6.80 (+0.15%)
PFE   28.67 (-0.42%)
PYPL   58.47 (-1.78%)
XOM   98.34 (-0.78%)

Ampliphi Biosciences Stock Price, News & Analysis (NYSEAMERICAN:APHB)

$2.50
-0.10 (-3.85%)
(As of 12/6/2023 ET)
Compare
Today's Range
$2.50
$2.60
50-Day Range
N/A
52-Week Range
$0.15
$1.37
Volume
29,156 shs
Average Volume
842,200 shs
Market Capitalization
$83.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

APHB stock logo

About Ampliphi Biosciences Stock (NYSEAMERICAN:APHB)

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

APHB Stock Price History

APHB Stock News Headlines

Recent Reports Are A Wake-Up Call For Investors
As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
AmpliPhi Biosciences and C3J Therapeutics Agree to Merge
See More Headlines
Receive APHB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampliphi Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/25/2019
Today
12/07/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:APHB
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$83.67 million
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Paul C. Grint (Age 61)
    CEO & Director
  • Mr. Steven R. Martin (Age 58)
    Sr. VP & CFO
  • Mr. Michael Scott Salka (Age 57)
    Consultant














APHB Stock Analysis - Frequently Asked Questions

How were Ampliphi Biosciences' earnings last quarter?

Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) posted its quarterly earnings data on Monday, March, 25th. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.07.

What other stocks do shareholders of Ampliphi Biosciences own?
How do I buy shares of Ampliphi Biosciences?

Shares of APHB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:APHB) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -